Job Title: Fundraising Intern Department: Development Status: Exempt The Lymphoma Research Foundation seeks a highly motivated intern to support fundraising efforts within the Development department. Located in New York City, the Lymphoma Research Foundation is the nation’s largest non-profit organization devoted to funding innovative research and…
Researcher Spotlight: Anli Zhang, PhD The University of Texas Southwestern Medical CenterChike Springer Legacy Scholar Dr. Zhang is an instructor at UT Southwestern Medical Center in the field of cancer and immunology. She earned her doctoral degree at Fudan University…
Researcher Spotlight: Reid Shaw, MD The University of ChicagoErrol M. Cook Memorial Scholar For some patients with relapsed or refractory large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR) T-cell therapy can produce dramatic and even curative responses; however, less than…
Researcher Spotlight: John Patton, MD, PhD The Ohio State UniversityWarwick Foundation Scholar Many lymphomas increase protein production to grow, survive, and evade the immune system. A key helper in this process is a molecule known as eIF4A. When eIF4A is…
Researcher Spotlight: Anouchka Laurent, PhD The Trustees of ColumbiaUniversity in the City of New York Dr. Laurent is an assistant research scientist in the Institute for Cancer Genetics at Columbia University in New York. She completed her doctoral research at…
Researcher Spotlight: Makoto Iwasaki, MD, PhD Massachusetts General HospitalHarwood Family Scholar Most cancer-related genetics research focuses on the small fraction of human DNA that harbors protein-encoding genes. However, most of the genome consists of much larger “non-coding” regions, which include…
Researcher Spotlight: Amin Aalipour, MD, PhD Dana-Farber Cancer InstitutePaul Walker Schaffel Scholar Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment option for many patients with lymphoma, but many patients still eventually relapse with time. Understanding the…
Researcher Spotlight: Graham Wehmeyer, MD Icahn School of Medicine at Mount SinaiKanti R. Rai, MD Clinical Scholar Doxorubicin is a commonly used chemotherapy regimen that can be very effective against different types of lymphoma. However, doxorubicin can also cause damage…
Researcher Spotlight: Efrat Luttwak, MD, MPH Memorial Sloan Kettering Cancer CenterCondon Family Scholar Transformed follicular lymphoma (FL) is an aggressive type of lymphoma for which there remains no clearly established standard approach to treatment. Dr. Luttwak’s research aims to develop…
Researcher Spotlight: Hunter Cochran, MD Washington University in St. LouisKellie and Jeff Fellinge Scholar Many traditional immunotherapies for lymphomas work by broadly suppressing the immune system. Dr. Cochran’s research focuses on the development of a personalized cancer vaccine for patients…
